CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model

Large cell lung carcinoma (LCLC) is one form of NSCLC that spreads more aggressively than some other forms, and it represents an unmet medical need. Here, we investigated for the first time the effect of the anti-CK2 CIGB-300 peptide in NCI-H460 cells as an LCLC model. NCI-H460 cells were highly sen...

Cijeli opis

Bibliografski detalji

Glavni autori:	George V. Pérez, Mauro Rosales, Ailyn C. Ramón, Arielis Rodríguez-Ulloa, Vladimir Besada, Luis J. González, Daylen Aguilar, Dania Vázquez-Blomquist, Viviana Falcón, Evelin Caballero, Paulo C. Carvalho, Rodrigo Soares Caldeira, Ke Yang, Yasser Perera, Silvio E. Perea
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2022-12-01
Serija:	Biomedicines
Teme:	lung cancer LCLC CK2 CIGB-300
Online pristup:	https://www.mdpi.com/2227-9059/11/1/43
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!